Neuren Pharmaceuticals Ltd (AU:NEU) — Market Cap & Net Worth
Market Cap & Net Worth: Neuren Pharmaceuticals Ltd (NEU)
Neuren Pharmaceuticals Ltd (AU:NEU) has a market capitalization of $1.16 Billion (AU$1.65 Billion) as of June 19, 2026. Listed on the AU stock exchange, this Australia-based company holds position #8419 globally and #209 in its home market, demonstrating a -3.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neuren Pharmaceuticals Ltd's stock price AU$12.99 by its total outstanding shares 126639526 (126.64 Million). Review Neuren Pharmaceuticals Ltd debt and liabilities to assess the company's total debt and financial obligations.
Neuren Pharmaceuticals Ltd Market Cap History: 2015 to 2026
Neuren Pharmaceuticals Ltd's market capitalization history from 2015 to 2026. Data shows growth from $206.09 Million to $1.16 Billion (19.28% CAGR).
Index Memberships
Neuren Pharmaceuticals Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
S&P/ASX All Australian 200
AXAT
|
$1.93 Trillion | 0.06% | #147 of 200 |
|
S&P/ASX 300
AXKO
|
$2.18 Trillion | 0.05% | #172 of 300 |
|
ASX Small Ordinaries
AXSO
|
$304.81 Billion | 0.38% | #83 of 200 |
Weight: Neuren Pharmaceuticals Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Neuren Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neuren Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.25x
Neuren Pharmaceuticals Ltd's market cap is 5.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.89x
Neuren Pharmaceuticals Ltd's market cap is 7.89 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $206.09 Million | $1.67 Million | -$13.40 Million | 123.19x | N/A |
| 2016 | $103.94 Million | $3.15 Million | -$12.01 Million | 33.00x | N/A |
| 2017 | $286.74 Million | $631.00K | $3.29 Million | 454.42x | 87.21x |
| 2018 | $125.45 Million | $13.99 Million | $3.07 Million | 8.97x | 40.82x |
| 2019 | $222.22 Million | $495.00K | -$10.82 Million | 448.93x | N/A |
| 2020 | $115.14 Million | $717.00K | -$9.19 Million | 160.59x | N/A |
| 2021 | $337.81 Million | $3.20 Million | -$7.79 Million | 105.67x | N/A |
| 2022 | $712.36 Million | $14.55 Million | $184.00K | 48.95x | 3871.54x |
| 2023 | $2.24 Billion | $231.93 Million | $157.08 Million | 9.65x | 14.24x |
| 2024 | $1.12 Billion | $213.24 Million | $142.04 Million | 5.25x | 7.89x |
Competitor Companies of NEU by Market Capitalization
Companies near Neuren Pharmaceuticals Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Neuren Pharmaceuticals Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Neuren Pharmaceuticals Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Neuren Pharmaceuticals Ltd's market cap moved from $206.09 Million to $ 1.16 Billion, with a yearly change of 19.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$1.16 Billion | -30.20% |
| 2025 | AU$1.67 Billion | +48.88% |
| 2024 | AU$1.12 Billion | -49.94% |
| 2023 | AU$2.24 Billion | +214.09% |
| 2022 | AU$712.36 Million | +110.88% |
| 2021 | AU$337.81 Million | +193.39% |
| 2020 | AU$115.14 Million | -48.19% |
| 2019 | AU$222.22 Million | +77.14% |
| 2018 | AU$125.45 Million | -56.25% |
| 2017 | AU$286.74 Million | +175.86% |
| 2016 | AU$103.94 Million | -49.57% |
| 2015 | AU$206.09 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Neuren Pharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.16 Billion USD |
| MoneyControl | $1.16 Billion USD |
| MarketWatch | $1.16 Billion USD |
| marketcap.company | $1.16 Billion USD |
| Reuters | $1.16 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 cl… Read more